News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article analyzes Grupo Aeroportuario Del Centro Norte S.a.b. De C.v. (NASDAQ: OMAB) through technical signals, indicating conflicting sentiment and choppy conditions. It presents institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide potential trading actions. The …
Agomab Therapeutics (AGMB) has announced a special and extraordinary general shareholders' meeting for September 11, 2026, in Antwerp, Belgium. The company plans to propose the appointment of Marino Garcia and Dr. Naimish Patel as non-executive directors for four-year terms, subject to shareholder approval. Additionally, …
Erik Otto, an investor in Chemomab Therapeutics Ltd. (CMMB), has filed an amended Schedule 13G, disclosing beneficial ownership of 90,000 American Depository Shares (ADSs), which represents 1.2% of the company's outstanding ADSs. Each ADS represents twenty ordinary shares. Otto holds sole voting and dispositive …
Agomab Therapeutics NV announced the proposed appointments of Marino Garcia and Dr. Naimish Patel to its Board of Directors, pending shareholder approval at a Special General Meeting on September 11, 2026. Marino Garcia brings extensive experience in biotechnology leadership and financing, currently serving as …
AgomAb Therapeutics NV's average 12-month price target has been lowered slightly from $34.2 to $33.16 by six analysts, with forecasts ranging from $27.96 to $36.27 per share. Despite the cut, this updated target still suggests a significant upside of approximately 146% from its recent …
Chemomab Therapeutics Ltd (CMMB) has a "Strong Buy" rating based on 2 analysts, with a target price of USD 26.50, representing a potential upside of 733.33%. The company's previous quarter's EPS was USD -0.24, slightly below the market expectation of USD -0.22, with the …
Grupo Aeroportuario del Centro Norte SAB de CV (OMAB) has an earnings forecast score of 8.00, ranking 3rd in the Transport Infrastructure industry. Analysts have set an average price target of $115.00 for OMAB, with most recommending a "Buy" trend. The company's expected revenue …
Agomab Therapeutics NV reported its financial results for the first half of 2026, confirming its outlook for the second half of the year. The company successfully completed its Nasdaq IPO, raising $208 million, which is expected to fund operations into the first half of …
Agomab Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of €30.97 million for the first half of 2026 but secured its financial future by raising $208 million in gross proceeds from a Nasdaq IPO. This capital infusion, bringing their total cash and investments …
Agomab (Nasdaq: AGMB) reported a net loss of €31.0 million for the first half of 2026, with €252.0 million in cash and short-term investments as of June 30, 2026. This cash position, bolstered by a $208 million IPO, is expected to fund operations into …
Chemomab Therapeutics (Nasdaq:CMMB) is a clinical-stage biotechnology company focused on treatments for fibrotic and inflammatory diseases. The company faces significant risks, including a highly volatile share price, shareholder dilution, and projected earnings decline, with recent news dominated by a proposed reverse merger with Scipher …
Grupo Aeroportuario del Centro Norte (OMA) released its 2025 Sustainability Report, detailing significant progress on environmental, social, and governance (ESG) commitments. Key achievements include an 88% reduction in Scope 1 and 2 carbon emissions per passenger, 87% electricity from renewable sources, and a 15% …
Grupo Aeroportuario del Centro Norte (OMA) reported a 3.9% increase in terminal passenger traffic across its 13 airports in July 2026 compared to July 2025. Domestic traffic rose by 3.3%, while international traffic saw a stronger growth of 7.5%. Commercial passengers constituted 99.5% of …
AgomAb Therapeutics (NASDAQ:AGMB), despite being unprofitable, is considered to have a manageable cash burn. With €117m in cash reserves and a burn rate of €52m per year, the company has a cash runway of about 2.3 years. While its cash burn increased by 8.9% …
Certain warrants of AgomAb Therapeutics NV are under a lock-up agreement set to expire on August 5, 2026. These warrants will be locked up for a period of 181 days, beginning February 5, 2026. The agreement applies to directors, executive officers, and substantially all …
This article provides a stock analysis of AgomAb Therapeutics (AGMB), a clinical-stage biopharmaceutical company. It highlights the company's financial
Grupo Aeroportuario del Centro Norte SAB de CV (OMAB) has a current risk assessment score of 8.40, ranking 3 out of 5 in the Transport Infrastructure industry. The company's beta is 0.60, indicating it tends to underperform during market upturns but experience smaller declines …
This article provides a detailed financial overview of Chemomab Therapeutics Ltd (CMMB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for …
This article focuses on the enterprise value to revenue forward of AgomAb Therapeutics NV (NASDAQ:AGMB). It provides a high-level overview of the company's financials as presented on TradingView. The content itself is very minimal, serving more as a title for a financial data point …
This article details precision trading strategies for Grupo Aeroportuario Del Centro Norte S.a.b. De C.v. (OMAB), highlighting a strong near-term sentiment but neutral mid and long-term outlook. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry zones, …
Sharemaestro market context Price below Trend Line 52 weeks -7.1% · Next-week setup positive 55.5%Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (BMV:OMAB) reported a 13% revenue beat, with revenues of Mex$4.5b and statutory earnings per share (EPS) of Mex$3.80, which were in line with analyst forecasts. Despite the beat, analysts have largely maintained their 2026 revenue and …
Grupo Aeroportuario del Centro Norte SAB de CV (OMAB) has an institutional shareholding score of 3.00, placing it first in the Transport Infrastructure industry. The latest institutional shareholding proportion is 12.67%, marking a 6% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding …
Sharemaestro market context Price below Trend Line 52 weeks -7.1% · Next-week setup positive 55.5%This article provides a brief snapshot of AgomAb Therapeutics NV's (NASDAQ: AGMB) "Price to sales forward" metric. It appears to be a financial data point from TradingView, indicating a period value, change, and percentage change. The article focuses on presenting this specific financial data …
This article first appeared on GuruFocus. Passenger Traffic: 1.2 million passengers served, a 0.4% increase year-over-year. Domestic Passenger Traffic Growth: Increased by 0.6%. International Passenger Traffic Decline: Decreased by 1.2%. Aeronautical Revenues: Increased by 4%. Commercial Revenues: Increased by 7%. Commercial Revenue per Passenger: …
Grupo Aeroportuario del Centro Norte (OMA) reported strong financial results for Q2 2026, with a consolidated net income of Ps.1,478 million, a 10.2% increase year-over-year. The company also announced an 88% reduction in Scope 1 and 2 emissions per passenger, exceeding its sustainability-linked bond …
Search by ticker symbol or company name and select a result to open its chart.